AVITA Medical, Inc. (RCEL) Earnings Call Transcripts
AVITA Medical, Inc.'s Latest Earnings Call - June 3, 2026
In the 2026 Annual Stockholders Meeting held on June 3, AVITA Medical, Inc. reported no significant changes in revenue or earnings, as the meeting primarily focused on governance matters rather than financial performance. The company confirmed that all proposals received the requisite votes to pass, indicating strong shareholder support. However, there were no updates on financial guidance or metrics, leaving investors without new insights into future performance expectations.
Reported metrics
| Metric | Value |
|---|---|
| Proposals Passed | 15 (positive) |
| Shares Outstanding | 30,776,689 (neutral) |
| Quorum Established | 50% (positive) |
| Voting Results Announcement | Form 8-K (neutral) |
Guidance from management
There were no updates or changes to financial guidance provided during the meeting.
What management said
Thanks, Jan. The Board set April 9, 2026, is the record date for this annual meeting. I confirm that the company has received affidavits attesting to proper notice and the availability of proxy materials to all stockholders. Additionally, an annual report on Form 10-K for the fiscal year ended December 31, 2025, including certified financial statements, has been made available to all stockholders entitled to vote a...
Sure thing, Jan. I hereby confirm that as of the record date, there were a total of 30,776,689 shares of common stock, which includes the underlying shares of common stock represented by CDIs listed on the Australian Stock Exchange that were outstanding and entitled to vote as of that record date. The Inspector of Elections has confirmed that proxies representing more than 50% of such shares entitled to vote at today...
What analysts pressed on
Analysts expressed concerns over the lack of financial updates and guidance, which could impact investor sentiment. The absence of questions during the Q&A session may indicate a lack of clarity or interest in the company's financial trajectory.
Main topics on the call
- Shareholder Support — All 15 proposals presented at the meeting received the requisite votes to pass, demonstrating strong shareholder backing. Jan Stern Reed stated, "all proposals received the requisite for votes to pass in this year's meet...
- Lack of Financial Updates — The meeting did not include any financial performance metrics or guidance updates, which may leave investors seeking clarity on future revenue and earnings. There were no discussions on revenue or earnings projections fo...
- Governance Proposals — The meeting focused on governance proposals, including the election of directors and compensation matters, which were all approved. This reflects the company's commitment to maintaining strong governance practices.
- No Analyst Questions — There were no questions submitted by analysts during the Q&A session, indicating either a lack of concern or a desire for more substantial financial updates. Nicole Kelsey confirmed, "there have been no questions submitt...
Read the full AVITA Medical, Inc. transcript (June 3, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About AVITA Medical, Inc.
AVITA Medical, Inc. (RCEL) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 43 calls on record spanning February 28, 2022 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 43 AVITA Medical, Inc. earnings call transcripts on record, spanning February 28, 2022 to August 6, 2026. Based on this history, AVITA Medical, Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RCEL
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 43
- First call
- February 28, 2022
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly